Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $56.00 price objective on the stock.
Several other brokerages have also recently weighed in on MTSR. Evercore ISI started coverage on Metsera in a research note on Tuesday. They set an “outperform” rating for the company. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday. They set a “buy” rating and a $38.00 price objective for the company.
View Our Latest Stock Analysis on MTSR
Metsera Price Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- What Are Dividend Contenders? Investing in Dividend Contenders
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How to Calculate Inflation Rate
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- What is a Low P/E Ratio and What Does it Tell Investors?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
